FAQs
Q1. How do the two active ingredients in Dicfu-B Cream — Beclometasone and Fusidic Acid — work together?
A1. Dicfu-B Cream is formulated for skin infections where inflammation and bacterial activity co-exist. Beclometasone is a medium-potency topical corticosteroid (Class III–IV) that suppresses the inflammatory cascade by inhibiting cytokine production and reducing capillary permeability — it addresses the redness, swelling, heat, and itch that accompany infected eczema or impetiginised dermatitis. Fusidic Acid is a narrow-spectrum antibiotic that targets gram-positive bacteria, particularly Staphylococcus aureus (the bacterium most commonly causing secondary skin infections), by inhibiting bacterial elongation factor G — preventing bacterial protein synthesis and killing the infection. Together they simultaneously suppress the inflammation and eliminate the bacteria driving it. This is a prescription medication and must be used under a dermatologist's guidance.
Q2. What conditions is Dicfu-B Cream specifically intended to treat — is it for all skin infections?
A2. Dicfu-B Cream is indicated for inflammatory skin conditions complicated by bacterial infection — primarily secondarily infected eczema (atopic dermatitis with S. aureus colonisation), infected contact dermatitis, and infected seborrhoeic dermatitis. Fusidic Acid is gram-positive-specific; it is not effective against gram-negative bacteria or fungal infections. It should not be used for ringworm, candida infections, or gram-negative bacterial skin infections — these require different antimicrobial agents. Your dermatologist will confirm whether bacterial culture and sensitivity testing is needed before prescribing combination therapy.
Q3. How long can Dicfu-B Cream be used safely — what happens with prolonged use?
A3. The Beclometasone component carries the same risks as other medium-potency corticosteroids with extended use: skin atrophy, striae (stretch marks), telangiectasia, and perioral dermatitis. Fusidic Acid has its own concern — Staphylococcus aureus can develop resistance to Fusidic Acid relatively quickly when used as monotherapy; in combination formulations, resistance emergence is slower but still a reason to limit duration. Treatment courses are typically 7–14 days; never continue beyond what your dermatologist prescribed. If the infection does not respond within the expected timeframe, seek a review rather than extending treatment independently.
Q4. Can Dicfu-B Cream be used on the face for infected acne or infected eczema patches on the face?
A4. Facial skin is thinner than body skin and absorbs topical corticosteroids at a higher rate, increasing the risk of skin thinning, steroid rosacea, and perioral dermatitis. Medium-potency steroids like Beclometasone require particular caution on the face. When a dermatologist does prescribe it for facial use, the course is typically very short (3–5 days) and the thinnest possible layer is applied. For infected acne specifically, combination steroid-antibiotic creams are rarely the first choice — systemic antibiotics or topical clindamycin are preferred. Always confirm facial use explicitly with your prescribing dermatologist.
Q5. Is Dicfu-B Cream available without a prescription, and what should I do if my infection seems to be returning after completing the course?
A5. Dicfu-B Cream requires a valid doctor's prescription. Self-purchasing or repeating a prior course without a renewed prescription is not safe — the original diagnosis may have changed, resistance may have developed to Fusidic Acid, or the returning symptoms may represent a different condition requiring different treatment. If infection symptoms recur after completing the prescribed course, return to your dermatologist for re-evaluation. Swab culture is valuable in recurrent cases to confirm the bacterial species and antibiotic sensitivity, ensuring the next treatment course uses the most effective agent.
